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Abstract: In this paper we describe new actions of nimesulide and paracetamol in cultured 
peripheral neurons isolated from rat dorsal root ganglia (DRG). Both drugs were able to decrease 
in a dose-dependent fashion the number of cultured DRG neurons showing translocation 
of protein kinase C epsilon (PKCε) caused by exposure to 1 µM bradykinin or 100 nM 
  thrombin. In addition, the level of substance P (SP) released by DRG neurons and the level of 
preprotachykinin mRNA expression were measured in basal conditions and after 70 minutes or 
36 hours of stimulation with nerve growth factor (NGF) or with an inflammatory soup containing 
bradykinin, thrombin, endothelin-1, and KCl. Nimesulide (10 µM) significantly decreased the 
mRNA levels of the SP precursor preprotachykinin in basal and in stimulated conditions, and 
decreased the amount of SP released in the medium during stimulation of neurons with NGF or 
with the inflammatory soup. The effects of paracetamol (10 µM) on such response was lower. 
Nimesulide completely inhibited the release of prostaglandin E2 (PGE2) from DRG neurons, 
either basal or induced by NGF and by inflammatory soup, while paracetamol decreased PGE2 
release only partially. Our data demonstrate, for the first time, a direct effect of two drugs largely 
used as analgesics on DRG neurons. The present results suggest that PKCε might be a target for 
the effect of nimesulide and paracetamol, while inhibition of SP synthesis and release is clearly 
more relevant for nimesulide than for paracetamol mechanism of action.
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Introduction
In this paper we present a comparative study of mechanisms of action of nimesulide 
and paracetamol, drugs largely used as analgesics, in cultured rat dorsal root ganglia 
(DRG) neurons.
Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) with broad effects 
on inflammation and other biochemical processes leading to a multifactorial mode 
of action.1 Nimesulide is a preferential cyclo-oxygenase-2 (COX-2) inhibitor1–4 but 
its anti-inflammatory and analgesic action also involves activity on a wide range of 
inflammatory and pain mediators and intracellular pathways1,5 including an effect 
on synovial concentration of substance P (SP) in patients with knee osteoarthritis.6 
While some evidence of analgesic action of nimesulide has been linked to actions in 
the central nervous system,7 to our knowledge direct effects of nimesulide in isolated 
sensory neurons have not yet been reported.
Paracetamol is one of the most popular and commonly used drugs for the treatment 
of moderate pain, which still presents a challenge in terms of a satisfactory explanation 
of its well-established effects. Despite its antipyretic and analgesic activities, it has Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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almost no anti-inflammatory action and is a weak inhibitor of 
either COX-1 or COX-2.8,9 Contribution of several   possible 
mechanisms has been proposed at a variety of levels in the 
nociceptive pathway from the periaqueductal gray to the 
periphery.10–16
The epsilon isoform of protein kinase C (PKCε) is a very 
important peripheral effector of a number of inflammatory 
mediators, including bradykinin, prostaglandins, proteases, 
prokineticins, SP and others,17–21 which causes increased 
activation of nociceptors via action on transient receptor 
potential vanilloid member1 (TRPV1) and on tetrodotoxin 
(TTX)-insensitive sodium channels.22
The neuropeptide SP has long been associated with 
transmission of noxious stimuli.23 In the peripheral nervous 
system it is expressed in a subset of unmyelinated nociceptive 
sensory neurons and is transported to central and peripheral 
axonal terminals. Centrally, SP is released in the superficial 
lamina of the spinal cord dorsal horn, while in the periphery 
it is implicated in neurogenic inflammation.24–26 Despite its 
importance in pain transmission, little is known about SP 
modulation by anti-inflammatory and analgesic drugs.
In this paper we investigate in cultured DRG neurons 
the ability of nimesulide and paracetamol to decrease 
translocation of PKCε, to reduce preprotachykinin synthesis 
and the release of SP induced by inflammatory mediators, and 
to reduce prostaglandin E2 (PGE2) release from activated neu-
rons. We show that nimesulide and paracetamol share some 
novel mechanisms of action potentially relevant for their 
in vivo effects, although other effects are exclusively seen or 
are quantitatively stronger with nimesulide treatment.
Material and methods
Dorsal root ganglion primary cultures
Sprague Dawley rats (2–3 weeks old) were sacrificed 
under total anesthesia according to Italian and European 
legislation, with protocols in agreement with the guidelines 
of the Committee for Research and Ethical Issues of IASP.27 
Experimental work was also reviewed and approved by 
local institutional animal care and use committee. DRGs 
were   collected, incubated for 1 hour at 37°C with 0.125% 
collagenase (Worthington, Freehold, NJ), and mechanically 
dissociated, plated onto coverslips or Petri dishes pretreated 
with 10 µg/mL poly-L-lysine (Sigma-Aldrich, St Louis, MO) 
and 20 µg/mL laminin (Sigma-Aldrich, Milan, Italy), and 
  cultured in DMEM containing 1% penicillin/streptomycin, 
10% fetal bovine serum, 1% L-glutamine (Invitrogen, 
San Diego, CA), 1.5 µg/mL cytosine 1-d-arabinofuranoside 
(ARA-C, Sigma), as described previously.28 Neurons used 
for immunocytochemistry experiments were cultured in the 
presence of 100 ng/mL nerve growth factor (NGF) (Sigma) 
in order to improve bradykinin and thrombin receptor 
expression.29
immunocytochemistry
PKCε was visualized as previously described.18,19 In brief, 
rat DRG neurons cultured for 2–3 days in vitro were treated 
with bradykinin (BK, at 1 µM concentration) or throm-
bin (THR, 100 nM) for 30 seconds, and rapidly fixed for 
10 minutes at room temperature with paraformaldehyde 
(4% formaldehyde and 4% sucrose, dissolved in phosphate-
buffered saline (PBS)/distilled water 2:1). Stimulation 
solutions and then fixation solution were applied with an 
automated system (FSC-1, CV Scientific, Modena, Italy). In 
test   experiments, nimesulide or paracetamol (from Sigma) 
at different   concentrations were preapplied for 120 minutes 
or overnight (see Figure 1) and also added to BK and THR 
applied to coverslips. Dimethyl sulfoxide (DMSO) was used 
to prepare stock solutions of nimesulide and paracetamol, and 
the final concentration of DMSO applied to cells was always 
lower than 1:1000. Fixed cells were washed three times in 
PBS (with 0.1% fish skin gelatin to block nonspecific sites), 
permeabilized for 30 minutes at room temperature with   Triton 
X-100 (0.2% in PBS), and incubated overnight at 4°C with 
a polyclonal anti-PKCε antibody17 diluted 1:1000 in PBS-T/
gelatin (PBS with 0.05% Triton X-100). Coverslips were then 
incubated for 1 hour at room temperature with goat antirabbit 
IgG conjugated to the fluorophore Alexa Fluor 488 (1:200; 
Invitrogen), washed three times in PBS/gelatin, and visual-
ized using a confocal microscope (Leica SP2, Leica, Swit-
zerland). Activation of PKCε results in translocation from an 
entirely cytoplasmic location to the neuronal cell membrane 
(see Figure 1). Translocation was quantified by determining 
fluorescence intensity along a line positioned across the cell 
so as to avoid the nucleus (for details see Cesare et al17). 
Neurones in which intensity at the cell membrane was at 
least 1.5 times greater than the mean of cytoplasmic intensity 
were counted as positive.
Dorsal root ganglia stimulation  
and drug treatment
After 2–3 days in vitro, DRG cultures were stimulated for 
experimental procedures using either NGF (100 ng/mL) or a 
cocktail of inflammatory/proalgesic mediators (inflammatory 
soup, IS) of the following composition: 1 µM BK, 100 nM Journal of Pain Research 2011:4
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Figure 1 nimesulide and paracetamol inhibit protein kinase c epsilon (PKcε) translocation in dorsal root ganglia (DRg) sensory neurons. (A–B) confocal images of DRg 
neurons treated with bradykinin (BK, 1 µM) for 30 seconds and then fixed and stained for PCKε with a specific antibody. (A) typical behavior of an unresponsive neuron. 
(B) typical BK-responsive neuron showing translocation of PKcε to the plasma membrane. neurons treated with 100 nM thrombin (ThR) for 30 seconds would display 
similar behavior. Neurons fixed without prior treatment with BK or THR showed no sign of spontaneous translocation. Scale bar 10 µm. (C) The percentage of neurons 
showing PKcε translocation induced by 1 µM BK or (E) by 100 nM THR was significantly decreased by 2 hours preapplication of nimesulide at 1 or 10 µM concentration. 
Overnight treatment (OVn) did not result in larger inhibition (C–E). With paracetamol treatment only the largest concentration of drug tested (10 µM) significantly reduced 
translocation induced by BK (D) or by ThR (F). Further explanations in the text. Values are means ± seM obtained from 4–12 cultures. 
Notes: *P , 0.05, **P , 0.01 and ***P , 0.001 compared with control.
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THR, 100 nM endothelin-1, 25 mM KCl, dissolved in normal 
culture medium (DMEM + 10% FBS). Where appropriate, 
a concentration of 10 µM of tested chemicals (nimesulide 
or paracetamol, from Sigma) dissolved in DMSO was 
preapplied for 30 minutes to cultures before treatment with 
NGF and IS which was considered sufficient time to allow 
full onset of their effect before application of inflammatory 
mediators.
Cells were stimulated with either NGF or IS with or 
without the drugs for 70 minutes and 36 hours. At the end 
of these incubation periods, media and cells were collected 
for further processing as described below.
Measurement of sP and Pge2 in culture 
media
Quantitative determination of PGE2 was performed by the 
enzyme immunoassay using a commercially available EIA 
kit (Cayman Chemical Company, Ann Arbor, MI). The 
sensitivity of the PGE2 EIA kit was 15 pg/mL.
To measure SP, culture media were acidified with 1N 
acetic acid and SP was measured by radioimmunoassay 
(RIA) using antiserum and methods previously described 
and validated.30,31 The antibody was raised in rabbit against 
synthetic SP, and was directed towards the C terminal of the 
peptide. I125-SP was purchased from Perkin Elmer (Monza, 
Italy). Sensitivity of the RIA was 10 pg/tube and intra-assay 
and inter-assay variation coefficients were 8% and 11%, 
respectively.
RnA isolation and real-time RT-PcR
Total RNA from DRG cells was purified using TRIzol reagent 
(Invitrogen, Life Technologies, San Giuliano Milanese, Italy). 
Cells were lysed directly in the culture dish, according to the 
manufacturer’s instructions and RNA resuspended in 8 µL 
of water. After purification, total RNA concentrations were 
determined from the sample absorbance value at 260 nm. 
Total RNA (300 ng) was treated with DNase (DNA-free-
Ambion) to avoid false-positive results due to amplification 
of contaminating genomic DNA. First-strand cDNA was 
synthesized from 1000 ng of total RNA in a final volume of 
20 µL using M-MLV RT (Moloney Murine Leukemia Virus 
Reverse Transcriptase; Invitrogen, San Giuliano Milanese, 
Italy). cDNA (2 µL) was subjected to real-time quantita-
tive PCR using ABI PRISM 7000 (Applied Biosystems, 
Forster City, CA). TaqMan PCR was performed in 25 µL 
volumes using Real Master Mix Probe ROX (Eppendorf, 
Hamburg, Germany). Custom probes were prepared by 
Applied Biosystems. The probes were the same as those 
used in a previous study31 and were designed to span an 
intron in order to avoid potential amplification of genomic 
DNA in the analyzed samples. The probes were labelled at 
the 5´ end with 6-carboxy fluorescein and at the 3´ end with 
6-carboxy-tetramethyl rhodamine. The primers and probe 
sequence for preprotachykinin (PPT, Genbank accession 
number M15191) and GAPDH (Genbank accession number 
AF106860) are shown in Bianchi et al.31 All PCR assays were 
performed in duplicate. Before using the ∆∆CT method for 
relative quantification, we performed a validation experiment 
to demonstrate that the efficiencies of the two different probes 
(target and reference) are equal. The reaction conditions 
were as follows: 95°C for 2 minutes, followed by 40 cycles 
at 95°C for 15 seconds (denaturation) and 60°C for 1 minute 
(annealing and elongation). As controls, we used the reac-
tion mixture without the cDNA. Threshold cycle numbers 
(CT) were determined with an ABI PRISM 7000 Sequence 
Detection System (version 1.1 software) and transformed 
using the ∆CT (2-∆∆CT) comparative method. Gene-specific 
expression values were normalized to expression values of 
GAPDH (endogenous control) within each sample. The levels 
of preprotachykinin were expressed relative to the calibrator 
value control cells. Relative quantification was performed 
using the comparative method. The amount of target, normal-
ized to an endogenous reference and relative to a calibrator, 
is given by 2-∆∆CT. Briefly, the ∆CT value is determined 
by subtracting the average GAPDH CT value from the aver-
age PPT CT in the same sample. The calculation of ∆∆CT 
involves subtraction of the ∆CT calibrator value.
statistical analysis
Data were analyzed by one way analysis of variance 
(ANOVA), followed by Bonferroni’s t-test for multiple 
comparison. An effect was determined to be significant if 
the P value was less than 0.05.
Results
effects on PKcε translocation
Activation of PKCε by inflammatory mediators leads to its 
translocation from the cytoplasm to the surface membrane 
in DRG sensory neurons, which can be visualized directly 
with immunocytochemistry and confocal microscopy 
(Figure 1A and B).18,19,21 PKCε translocation can be quanti-
fied in terms of the number of neurons in which translocation 
is observed – with this approach reliable dose-response and 
time-course curves can be obtained.19,21 After application of 
1 µM BK or 100 nM THR, which are saturating   concentrations 
for these agonists, maximum translocation was consistently Journal of Pain Research 2011:4
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Figure 2 effect of nimesulide and paracetamol (10 µM) on preprotachykinin (PPT) 
mRnA expression in cultured dorsal root ganglia neurons in basal conditions and 
following 36 hours treatment with inflammatory soup (IS) and with nerve growth 
factor (ngF). The amount of PPT is normalized to gAPDh by subtracting the average 
gAPDh cycle numbers (cT) value from the average PPT cT and then the comparative 
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Abbreviations: P, paracetamol; n, nimesulide.
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observed. At longer application times PKCε slowly became 
internalized into perinuclear vesicles as shown previously.17,19,21 
As maximum translocation was consistently observed with 
the above agonist concentrations and at 30-second exposure, 
these parameters were adopted for all subsequent experiments. 
BK applied onto DRG cultures for 30 seconds at 1 μM before 
rapid fixation caused translocation in 30.8% ± 2% of neonatal 
rat neurons cultured in the presence of NGF. THR caused 
translocation in 17.8% ± 1% of neonatal rat DRG neurons, 
also cultured in the presence of NGF.
As shown in Figure 1C, the number of neurons in which 
1 µM BK induced translocation was significantly decreased 
by 2 hours preapplication of nimesulide (10 µM) to a value 
of 17.9% ± 1.1% compared with neurons pretreated with 
vehicle solution (P , 0.001). Translocation was also signifi-
cantly reduced by a 10-fold lower concentration of nimesulide 
(1 µM) to 22.9% ± 2.5%, and efficacy was significantly smaller 
compared with 10 µM nimesulide (P , 0.05), indicating that 
nimesulide effect was dose-dependent. Nimesulide had largely 
similar effects on translocation of PKCε induced by 100 nM 
THR (Figure 1E), and in this case inhibition was statistically 
significant although not significantly different at 10 µM 
(11.1 ± 1.4) and 1 µM concentrations (12.5 ± 1.7), which were 
preapplied for 2 hours before the experiment. Longer preap-
plication of nimesulide at 10 µM (overnight rather than of 
2 hours) did not cause a larger inhibition of translocation, both 
for BK (14.3% ± 1.7%) and for THR (10.4% ± 1.2%) as shown 
in Figure 1C and E. Shorter preapplication of nimesulide for 
15 minutes at 10 µM concentration did not cause significant 
differences compared with 120-minute application, and in this 
case 1 µM BK caused translocation in 17.4 ± 0.5% and 100 nM 
THR in 9.6% ± 1.2% of neurons (not shown in figure).
The effect of paracetamol on PKCε translocation 
was tested with an identical protocol as the one used for 
nimesulide. As shown in Figure 1D and F paracetamol was 
less effective than nimesulide, because only the highest 
  concentration tested decreased the percentage of translocated 
neurons significantly. While nimesulide at 10 µM caused a 
percentage of decrease of translocation induced by BK and 
THR of ∼42% and ∼38%, paracetamol at the same concen-
tration caused a decrease of ∼23% and ∼34% respectively. 
The effect of paracetamol, like that of nimesulide, did not 
increase with overnight preapplication.
effects on preprotachykinin mRnA 
synthesis
SP is synthesized from the precursor PPT. PPT mRNA was 
quantified in DRG cultures using real time PCR.31 We used 
as baseline, cultures in the absence of treatments and with no 
addition of growth factors 60 hours after plating, at which time 
relevant PTT mRNA levels were consistently above minimal 
levels for detection. PPT levels were significantly upregulated 
compared with control by 36 hours of treatment with NGF 
(100 ng/mL) or with a mixture of proinflammatory and proal-
gesic agents which we termed IS (see Materials and methods). 
Both treatments were effective in different trials, and upregula-
tion by IS increased mRNA levels by about 2.9-fold compared 
with control while NGF-induced increase ranged from 1.7 to 
2.9 compared with control (see Figure 2A and B).
Nimesulide treatment (10 µM) applied 24 hours after 
plating for 36 hours significantly decreased basal level of PPT 
mRNA compared with untreated neurons. Nimesulide also 
significantly reduced upregulation of PPT mRNA caused by 
IS and NGF respectively of ∼40 and ∼60% (Figure 2A).Journal of Pain Research 2011:4
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Effects of paracetamol (Figure 2B) were somewhat 
different: at 10 µM after 36 hours of treatment it did not 
cause any change in basal expression levels of PPT mRNA, 
and significantly reduced upregulation by IS (by ∼40%), 
while upregulation by NGF was not changed by treatment. 
Both nimesulide and paracetamol were preapplied for 
30 minutes to allow full onset of effect before treatment 
with IS and NGF.
effects on basal and stimulated substance 
P release in medium
Levels of SP released in the medium by cultured DRG 
neurons were assessed by radioimmunoassay (see Materials 
and methods). Approximately 24 hours after plating, separate 
coverslips from the same DRG cultures were treated with 
either nimesulide, paracetamol (both 10 µM), with or 
without NGF (100 ng/mL) or IS, or with vehicle, for a total 
of 6 separate conditions (Figure 3A–D). Coverslips exposed 
to treatments containing nimesulide or paracetamol were 
pre-treated with the same concentration of these drugs 
for 30 minutes, and control coverslips were treated with 
vehicle medium for the same time. The treatments described 
remained on coverslips for either 70 minutes (Figure 3A 
and B) or 36 hours (Figure 3C and D), then the medium was 
removed and stored at –80°C until SP measurement.
Neither nimesulide nor paracetamol altered basal levels 
of release of SP, which were about 30 ± 2.19 (mean ± SEM) 
pg/mL of medium at 70 minutes and 77 ± 11 (mean ± SEM) 
pg/mL medium at 36 hours.
Treatment with both NGF and IS significantly increased 
SP level in medium after 70 minutes and after 36 hours 
 ( Figure 3A–D). Such release was significantly decreased 
by nimesulide (Figure 3A and C) but was not changed 
by paracetamol, which was completely ineffective 
 ( Figure 3B and D). Nimesulide effect was significant after 
70 minutes, and was particularly strong after 36 hours, as Journal of Pain Research 2011:4
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SP release caused by NGF and IS was totally inhibited and 
reduced to values largely identical to basal levels.
effects on Pge2 release in medium
PGE2  was  quantified  in  DRG  cultures  using  an  EIA   
(see Figure 4A).31,32 In culture medium there was little if 
any PGE2 as only traces were contributed by the 10% fetal 
bovine serum added to DMEM (see methods). Approximately 
24 hours after plating, the medium was changed and cultures 
treated either with vehicle or with IS, NGF, with or without 
nimesulide or paracetamol (10 µM). After 70 minutes or 
36 hours of treatment, the medium was collected and PGE2 
released by cultures during this time measured. Basal release 
by unstimulated DRG cultures in different sets of experiment 
levels ranged between 199 ± 41 and 337 ± 37 pg/mL after 
70 minutes and between 1.5 ± 0.5 and 1.7 ± 0.5 ng/mL after 
36 hours. PGE2 levels were significantly increased compared 
with control by 70 minutes or 36 hours of treatment with 
NGF or IS. Both treatments were effective in different   trials, 
and IS augmented PGE2 levels by about 1.6- to 2.3-fold     
compared with control, while NGF increase ranged between 
1.5 and 2.0-fold after 70 minutes; the increase ranged between 
4.8- and 7.4-fold (IS) and 4.6- and 4.2-fold (NGF) after 
36 hours compared with control levels (see Figure 4) in dif-
ferent groups of experiments. Nimesulide treatment (10 µM) 
applied 24 hours after plating for 70 minutes or 36 hours 
(Figure 4A and C) completely inhibited PGE2 basal levels 
released in medium compared with untreated neurons (reduc-
tion by almost 100%). Nimesulide treatment also completely 
inhibited the release of PGE2 caused by IS and NGF. Both at 
70 minutes and 36 hours nimesulide reduced PGE2 down to 
levels similar to those present in the medium before it was 
added to cultures (Figure 4A and C).
Paracetamol (Figure 4B and D) (10 µM) decreased basal 
levels of PGE2 both after 70 minutes and 36 hours. Similarly, 
release of PGE2 induced by IS was significantly reduced 
by paracetamol both at 70 minutes and 36 hours. Differently, 
PGE2 release induced by NGF was significantly decreased by 
paracetamol after 70 minutes, while reduction after 36 hours 
(about 30%) did not reach statistical significance.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Discussion
Specific involvement of PKCε in nociceptor sensitization and 
hyperalgesia has been described in many reports. Following 
a first paper by Cesare et al,17 showing that sensitization of 
heat-induced currents by bradykinin in nociceptive neurons 
is mediated by PKCε, a number of studies confirmed the 
importance, participation, and requirement of this enzyme 
in inflammatory pain and nociception at the cellular and 
whole-animal level.22,33,34 PKCε is preferentially expressed in 
nociceptive neurons where it plays a crucial role in chronic 
hyperexcitability, but its inhibition causes little disruption in 
normal sensory function or in other functions.34 PKCε therefore 
currently represents not only a well-validated target for both 
inflammatory and neuropathic pain in the preclinical scientific 
literature35,36 but also a novel and appealing   target for therapeutic 
intervention in human patients. In this light, our novel finding 
of PKCε translocation inhibition by nimesulide and, although to 
a lesser extent, by paracetamol, appears to be of high relevance 
for a better understanding of the mechanisms of action of these 
drugs. Work is currently in progress to investigate whether inter-
ference on PKCε translocation is a common feature of other 
NSAIDs and analgesic drugs. PKCε inhibition by nimesulide, 
paracetamol, or possibly other NSAIDs and analgesics may be 
a relevant part of their pharmacological actions.
Prostaglandins work not only as mediators that directly 
activate downstream cascades leading to sensitization of 
nociceptor ion channels, but also function as paracrine media-
tors in nociceptor sensitization by other inflammatory agents 
(glutamate, bradykinin, thrombin etc). Prostaglandins may be 
produced by the inflamed tissues and by white bloods cells 
participating in inflammation, but also by sensory neurons 
and by peripheral glial cells. It is noteworthy that in DRG 
cultures, as in DRGs and in peripheral nerve endings, there 
is a significant presence of peripheral glial cells (satellite 
cells and Schwann cells) whose number, despite the presence 
of the cell replication inhibitor ARA-C (see Materials and 
methods), is in at least a 10:1 ratio compared with neurons. 
These cells express many of the receptors of inflammatory 
mediators expressed by nociceptors, and release prostaglan-
dins as well as other mediators, including endocannabinoids37 
or cytokines.38 Release of PGE2 from DRG cultures39 may 
be due to release from these non-neuronal cells. In fact in 
preliminary experiments (not shown here) we found a large 
release of PGE2 by cultures of non-neuronal peripheral glial 
cells after treatment with inflammatory mediators. Effects of 
PGE2 release inhibition from DRG cultures by nimesulide 
and paracetamol described in this paper may therefore be 
due to inhibition of non-neuronal and neuronal COXs. Both 
COX-1 and COX-2 are expressed in DRG neurons, with 
COX-1 especially expressed in small-sized sensory neurons,40 
while the identity of COXs expressed in peripheral glia is 
less clear.39,41
DRG cultures released considerable amounts of PGE2 
which increased significantly very quickly when IS and NGF 
were added to the medium. The blocking effect of nimesulide 
at the concentration used (10 µM) appeared to be maximum, 
as nimesulide completely suppressed both basal and induced 
PGE2 synthesis in DRG cultures. On the contrary, inhibition 
of PGE2 release caused by paracetamol was significantly 
smaller compared with the effect of nimesulide, consistent 
with current knowledge of paracetamol pharmacology and 
mechanisms of action.
Peripheral inflammatory pain is associated with a 
complex pattern of local changes, and after tissue injury 
many pronociceptive and proinflammatory mediators 
become activated; they lower nociceptive thresholds 
and increase   neuronal membrane excitability, leading to 
hypernociception.42,43 The neuropeptide SP is present in 
C-fibers, is synthesized in DRG, and is transported to both 
central and peripheral endings of primary afferent neurons. 
In the central nervous system, SP plays a crucial role in spi-
nal neuron sensitization. At the periphery, SP induces vaso-
dilatation, increases the sensitivity to nociceptive stimuli, 
and contributes to neurogenic inflammation.24 In addition, SP 
can directly activate immune cells inducing the chemotaxis 
of monocytes/macrophages, and the production of different 
proinflammatory cytokines.30,44,45 These effects contribute to 
the spreading of sensitization leading to secondary hyperal-
gesia. The control of both central and peripheral SP release 
is therefore a critical step in determination of the threshold 
of pain perception in hyperalgesia during inflammation.
Upon nociceptor stimulation, SP is released through a very 
complex process involving several important intracellular 
effectors such as extracellular calcium influx, 1-4-5 inositol 
triphosphate induced calcium release, the activation of 
ERK, PKA, COX, and prostaglandins. In order to induce 
SP synthesis and release we have used two different stimuli: 
NGF and a mix of inflammatory mediators (IS), which have 
been used all together in order to mimic the inflammatory 
soup that is present in the inflamed tissue. Both stimuli are 
potent activators of SP, as we observed a significant increase 
of SP release already after 70 minutes of stimulation while, 
as expected, a longer time was needed to upregulate the 
synthesis of preprotachykinin.
It appears that while the IS stimulus induced a repetitive 
and consistent increase of both preprotakikinin mRNA and Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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SP release across the different experiments, the modulation 
of the SP system by NGF, although always present, varied in 
the different cultures. It is likely that the IS, composed of 3 
different proinflammatory agents, is more potent than NGF 
since it activates several pathways and induces an almost 
maximal stimulation of the system. On the other hand, the 
NGF effect might be more sensitive to slight variations in 
experimental conditions in different batches of experiments 
such as the age of the animals and the different months of the 
year in which experiments were performed, which might have 
influenced the basal state of activation of the DRG cells and/
or the relative percentage of neurons and glial cells expressing 
NGF receptors in the cultures. Despite these quantitative 
variations in the amplitude of NGF response, the effects of 
the drugs tested appeared largely similar and consistent with 
other sets of experiments.
Our data show that the increase in synthesis and release 
of SP caused by IS and NGF was significantly reduced by 
nimesulide but not at all by paracetamol (Figure 3). Also 
basal levels of PPT mRNA were reduced by nimesulide, but 
again not by paracetamol. Given the in vitro system that we 
used in our experiment, and the rapid onset of the effect, the 
inhibition of SP release and production is likely to be due to 
a direct effect of nimesulide on nociceptors.
Our present data therefore suggest that sensory nerve 
fibers can be a target for nimesulide action and identify an 
important involvement of SP in the effects of nimesulide, 
indicating a further mechanism of action besides its well-
known inhibition of peripheral COX-2. On the contrary, 
modulation of SP levels does not appear to be part of the 
effects of paracetamol.
These observations add other elements to the growing 
number of effectors targeted by nimesulide, confirming the 
multifactorial basis for the actions of nimesulide. The details 
of the mechanisms by which nimesulide causes a decrease 
both in SP synthesis and release remains to be clarified. At 
the moment we can only speculate about the possibility that 
the inhibition of COX-1/2 present in DRG cells, as discussed 
above, leading to a reduction of PGE2 production might 
mediate, at least in part, the modulatory effect of nimesulide 
on SP. Despite a contribution of nimesulide-induced 
prostaglandin, a reduction in inhibition of SP release is 
possible, but is unlikely to be the only mechanism responsible. 
In fact paracetamol can also cause significant inhibition of 
prostaglandin but this is not paralleled by any decrease in 
SP release from DRGs (Figures 3 and 4). Interestingly, it has 
been suggested recently that the activation of TRPV1 channel 
is a strong stimulus for SP synthesis and release.46 As the 
sensitization of TRPV1 is partly due to PKCε-dependent 
phosphorylation, the possibility that nimesulide could 
downregulate SP throughout the reduction of PKCε 
translocation can be hypothesized. Moreover the binding of 
SP to its NK-1 receptors in primary sensory neurons enhances 
TRPV1 activity via PKCε.20 We can therefore envisage 
a positive feedback mechanism where SP, prostaglandin, 
TRPV1, and PKCε act in parallel and contribute to induce 
and maintain inflammatory hyperalgesia.
On the other hand, considering that paracetamol is also a 
weak inhibitor of PKCε but does not affect SP, we cannot rule 
out the possibility that the inhibition of translocation and the 
reduction of SP release are unrelated events. However, the 
effects of nimesulide on several crucial interacting mediators 
can be important in controlling not only acute hyperalgesia 
but also in preventing progression of inflammatory hyper-
algesia to chronicity. In a previous study nimesulide plasma 
concentrations were evaluated in patients after 2 weeks of 
treatment with an active dose of the drug. Interestingly, the 
measured nimesulide plasma levels were strictly in the range 
of the concentrations used in the present in vitro study, further 
indicating its relevance for in vivo effects of the drug.47
The effect of paracetamol and nimesulide investigated in 
this paper takes place in the peripheral nervous system. We 
need to remember that in vivo a large number of activities 
on several different targets may be involved in the effect 
of these drugs, and may be important in different, pain-
ful conditions. Supraspinal effects, which have been well 
described for paracetamol,48 are probably responsible for a 
large part of its analgesic activity. On the contrary, central 
mechanisms of nimesulide involved in its analgesic and 
antinflammatory effects are less recognized. We are also 
aware that our in vitro model is particularly representative of 
inflammatory hyperalgesia, and that further work is needed 
in order to evaluate the role of the pathways that we studied 
in other painful conditions, such as neuropathic pain.
Conclusion
Our data helped to clarify the pharmacological profile of 
nimesulide and paracetamol as analgesic drugs. From these 
results, nimesulide emerges as an NSAID with a multifacto-
rial mode of action and with a growing number of targets 
including the most recently identified and appealing ones.
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